ATE362763T1 - Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten - Google Patents
Substituierte carbostyrilderivate als 5-ht1a- subtyp agonistenInfo
- Publication number
- ATE362763T1 ATE362763T1 AT05023971T AT05023971T ATE362763T1 AT E362763 T1 ATE362763 T1 AT E362763T1 AT 05023971 T AT05023971 T AT 05023971T AT 05023971 T AT05023971 T AT 05023971T AT E362763 T1 ATE362763 T1 AT E362763T1
- Authority
- AT
- Austria
- Prior art keywords
- carbostyril derivatives
- subtype agonists
- substituted carbostyril
- ht1a subtype
- ht1a
- Prior art date
Links
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77021001A | 2001-01-29 | 2001-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE362763T1 true ATE362763T1 (de) | 2007-06-15 |
Family
ID=25087808
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05023971T ATE362763T1 (de) | 2001-01-29 | 2002-01-29 | Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten |
AT06015782T ATE504293T1 (de) | 2001-01-29 | 2002-01-29 | Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung |
AT02716434T ATE322894T1 (de) | 2001-01-29 | 2002-01-29 | Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06015782T ATE504293T1 (de) | 2001-01-29 | 2002-01-29 | Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung |
AT02716434T ATE322894T1 (de) | 2001-01-29 | 2002-01-29 | Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten |
Country Status (20)
Country | Link |
---|---|
EP (3) | EP1355639B1 (de) |
JP (4) | JP4178032B2 (de) |
KR (5) | KR100713607B1 (de) |
CN (3) | CN100450485C (de) |
AR (4) | AR032641A1 (de) |
AT (3) | ATE362763T1 (de) |
AU (4) | AU2002226752C1 (de) |
BR (1) | BR0206237A (de) |
CA (2) | CA2700314C (de) |
CY (3) | CY1105631T1 (de) |
DE (3) | DE60220325T2 (de) |
DK (3) | DK1621198T3 (de) |
ES (3) | ES2286755T3 (de) |
HK (2) | HK1061805A1 (de) |
MX (2) | MX344556B (de) |
MY (1) | MY129355A (de) |
PH (1) | PH12014500937A1 (de) |
PT (3) | PT1621198E (de) |
TW (2) | TWI331919B (de) |
WO (1) | WO2002060423A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
DE10148233A1 (de) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme |
US7973043B2 (en) * | 2002-07-30 | 2011-07-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
PT1575590E (pt) * | 2002-12-27 | 2007-12-06 | Otsuka Pharma Co Ltd | Derivados de carboestirilo e inibidores da reabsorção de serotonina para o tratamento de distúrbios de humor |
PL1626721T3 (pl) | 2003-05-23 | 2017-05-31 | Otsuka Pharmaceutical Co., Ltd. | Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
FR2865650B1 (fr) * | 2004-01-30 | 2008-06-13 | Biocortech | Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil |
WO2006090273A2 (en) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia |
US8227476B2 (en) * | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
TW200848041A (en) * | 2007-03-30 | 2008-12-16 | Otsuka Pharma Co Ltd | A medicament for treating schizophrenia comprising cilostazol |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
JP2009286740A (ja) * | 2008-05-30 | 2009-12-10 | Otsuka Pharmaceut Co Ltd | アリピプラゾールを含有する逆耐性抑制剤 |
EP2338873A1 (de) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | Neue Aminotetralinderivate |
AR090245A1 (es) | 2012-03-06 | 2014-10-29 | Otsuka Pharma Co Ltd | Preparacion solida oral de liberacion sostenida, metodo de preparacion |
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
JPS5646812A (en) * | 1979-09-27 | 1981-04-28 | Otsuka Pharmaceut Co Ltd | Central nervous system depressant |
US4764416A (en) * | 1986-07-01 | 1988-08-16 | Mitsubishi Denki Kabushiki Kaisha | Electric element circuit using oxidation-reduction substances |
US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神***病治療剤 |
ES2103374T3 (es) * | 1991-05-20 | 1997-09-16 | Upjohn Co | Derivados de carboxamido-(1,2n)-carbociclo-2-aminotetralina. |
US5532240A (en) * | 1991-12-26 | 1996-07-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Condensed thiophene compound and pharmaceutical use thereof |
AU5446894A (en) * | 1992-10-23 | 1994-05-24 | New York University | Functional interactions between glial s-100b and central nervous system serotonergic neurons |
DK148292D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Forbindelser |
JP2959615B2 (ja) * | 1993-06-24 | 1999-10-06 | 吉富製薬株式会社 | 縮合型チオフェン化合物およびその医薬用途 |
JPH09291034A (ja) * | 1996-02-27 | 1997-11-11 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピリジン化合物およびその医薬としての用途 |
US5688950A (en) * | 1996-04-23 | 1997-11-18 | Neurogen Corporation | Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands |
UA47467C2 (uk) * | 1996-05-07 | 2002-07-15 | Файзер Інк. | Тригідрат мезилату 5-(2-(4-(1,2-бензизотіазол-3-іл)-1-піперазиніл)етил)-6-хлор-1,3-дигідро-2(1н)-індол-2-ону (зипразидону), фармацевтична композиція та спосіб лікування психічних розладів |
JP4012994B2 (ja) * | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
CN1234023A (zh) * | 1996-08-27 | 1999-11-03 | 美国家用产品公司 | 作为多巴胺d2激动剂和5ht1a的配位体的4-氨基乙氧基吲哚 |
CN1289333A (zh) * | 1998-02-03 | 2001-03-28 | 美国家用产品公司 | 用作血清素-1a受体激动剂的噁唑衍生物 |
WO1999052870A1 (en) * | 1998-04-13 | 1999-10-21 | American Home Products Corporation | 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists |
JPH11335286A (ja) * | 1998-05-25 | 1999-12-07 | Mitsui Chem Inc | ドーパミン拮抗薬の効果増強剤 |
AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
EP1627639B1 (de) * | 2001-06-19 | 2009-12-23 | Norbert Müller | Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen |
AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
-
2002
- 2002-01-15 AR ARP020100118A patent/AR032641A1/es not_active Application Discontinuation
- 2002-01-25 TW TW093127321A patent/TWI331919B/zh not_active IP Right Cessation
- 2002-01-25 TW TW091101289A patent/TWI302832B/zh not_active IP Right Cessation
- 2002-01-26 MY MYPI20020297A patent/MY129355A/en unknown
- 2002-01-29 KR KR1020067014046A patent/KR100713607B1/ko active IP Right Grant
- 2002-01-29 PT PT05023971T patent/PT1621198E/pt unknown
- 2002-01-29 ES ES05023971T patent/ES2286755T3/es not_active Expired - Lifetime
- 2002-01-29 MX MX2011010975A patent/MX344556B/es unknown
- 2002-01-29 PT PT02716434T patent/PT1355639E/pt unknown
- 2002-01-29 DE DE60220325T patent/DE60220325T2/de not_active Expired - Lifetime
- 2002-01-29 AT AT05023971T patent/ATE362763T1/de active
- 2002-01-29 EP EP02716434A patent/EP1355639B1/de not_active Expired - Lifetime
- 2002-01-29 KR KR1020057019896A patent/KR100653591B1/ko active IP Right Grant
- 2002-01-29 DK DK05023971T patent/DK1621198T3/da active
- 2002-01-29 PT PT06015782T patent/PT1712225E/pt unknown
- 2002-01-29 AT AT06015782T patent/ATE504293T1/de active
- 2002-01-29 ES ES02716434T patent/ES2261652T3/es not_active Expired - Lifetime
- 2002-01-29 EP EP05023971A patent/EP1621198B1/de not_active Revoked
- 2002-01-29 KR KR1020077010561A patent/KR100825705B1/ko active IP Right Grant
- 2002-01-29 KR KR1020067005164A patent/KR100763288B1/ko active IP Right Review Request
- 2002-01-29 BR BR0206237-2A patent/BR0206237A/pt not_active Application Discontinuation
- 2002-01-29 EP EP06015782A patent/EP1712225B1/de not_active Revoked
- 2002-01-29 WO PCT/JP2002/000626 patent/WO2002060423A2/en active Application Filing
- 2002-01-29 DK DK06015782.3T patent/DK1712225T3/da active
- 2002-01-29 KR KR1020037008565A patent/KR100601073B1/ko active IP Right Grant
- 2002-01-29 ES ES06015782T patent/ES2363366T3/es not_active Expired - Lifetime
- 2002-01-29 DE DE60210581T patent/DE60210581T2/de not_active Expired - Lifetime
- 2002-01-29 DK DK02716434T patent/DK1355639T3/da active
- 2002-01-29 MX MXPA03006603A patent/MXPA03006603A/es active IP Right Grant
- 2002-01-29 JP JP2002560616A patent/JP4178032B2/ja not_active Expired - Lifetime
- 2002-01-29 CA CA2700314A patent/CA2700314C/en not_active Expired - Lifetime
- 2002-01-29 CN CNB2005100228288A patent/CN100450485C/zh not_active Expired - Lifetime
- 2002-01-29 AT AT02716434T patent/ATE322894T1/de active
- 2002-01-29 DE DE60239711T patent/DE60239711D1/de not_active Expired - Lifetime
- 2002-01-29 AU AU2002226752A patent/AU2002226752C1/en not_active Expired
- 2002-01-29 CA CA2429496A patent/CA2429496C/en not_active Expired - Lifetime
- 2002-01-29 CN CNA2006100943881A patent/CN1879624A/zh active Pending
- 2002-01-29 CN CNB028035518A patent/CN1239154C/zh not_active Expired - Lifetime
-
2004
- 2004-07-06 HK HK04104847A patent/HK1061805A1/xx not_active IP Right Cessation
-
2005
- 2005-04-27 AU AU2005201772A patent/AU2005201772C1/en not_active Expired
-
2006
- 2006-06-28 CY CY20061100884T patent/CY1105631T1/el unknown
- 2006-11-01 HK HK06111985.8A patent/HK1091403A1/xx not_active IP Right Cessation
-
2007
- 2007-04-17 AU AU2007201701A patent/AU2007201701B2/en not_active Expired
- 2007-07-09 JP JP2007179275A patent/JP4896831B2/ja not_active Expired - Lifetime
- 2007-08-20 CY CY20071101093T patent/CY1108031T1/el unknown
-
2009
- 2009-10-29 AU AU2009233591A patent/AU2009233591B2/en not_active Expired
-
2010
- 2010-12-28 AR ARP100104973A patent/AR079761A2/es not_active Application Discontinuation
-
2011
- 2011-04-08 AR ARP110101189A patent/AR080849A2/es not_active Application Discontinuation
- 2011-04-18 CY CY20111100391T patent/CY1111392T1/el unknown
- 2011-06-15 JP JP2011133033A patent/JP2011184460A/ja active Pending
- 2011-06-15 JP JP2011133032A patent/JP5683010B2/ja not_active Expired - Lifetime
-
2014
- 2014-04-28 PH PH12014500937A patent/PH12014500937A1/en unknown
-
2015
- 2015-03-13 AR ARP150100766A patent/AR099754A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE322894T1 (de) | Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten | |
ATE441631T1 (de) | Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer | |
ATE370137T1 (de) | 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren | |
ATE392897T1 (de) | Chinolinderivate als npy antagonisten | |
ATE377419T1 (de) | Substituierte 4-alkoxyoxazol derivate als ppar agonisten | |
ATE309996T1 (de) | Chinolinonderivate als tyrosin-kinase inhibitoren | |
IS8439A (is) | Nýjar kínólín afleiður | |
DE60136571D1 (de) | Guanidinobenzamide als mc4-r agonisten | |
ATE370120T1 (de) | Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate | |
DE60308850D1 (de) | Pyridinoylpiperidine als 5-ht1f agonisten | |
DE60225563D1 (de) | 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate | |
NO20041235L (no) | Kinolinderivater som neuropeptid Y antagonister | |
DE60207815D1 (de) | 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden | |
ATE396191T1 (de) | Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden | |
ATE335477T1 (de) | Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden | |
DE60203529D1 (de) | Indolderivate als cox-ii-inhibitoren | |
ATE413879T1 (de) | ß(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)- ETHYLAMINO)- PROPYLPHENYL-DERIVATE ALS BETA2 AGONISTEN | |
ATE306265T1 (de) | Benzothiazolderivate als adenosin-rezeptor- liganden | |
EE200300447A (et) | Asendatud bensofuraan-2-karboksamiidide derivaadid | |
ATE428420T1 (de) | Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer | |
ATE395333T1 (de) | 4-phenylpiperazinyl, -piperidinyl und - tetrahydropyridyl-derivate als dopamin d4- antagonisten | |
ATE281435T1 (de) | Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren | |
ATE309994T1 (de) | Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten | |
ATE410428T1 (de) | Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten | |
DE60201463D1 (de) | Indanon-Derivate als Duftstoffe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1621198 Country of ref document: EP |